Travere Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TVTX research report →
Range $67 – $89
Price Chart
About the company
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II).
- CEO
- Eric Dube
- IPO
- 2012
- Employees
- 497
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on TVTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.51B
- P/E
- -30.13
- Fwd P/E
- 15.66
- PEG
- 0.26
- P/S
- 6.93
- P/B
- 196.93
- EV/EBITDA
- -51.03
- Div Yield
- 0.00%
- Gross Margin
- 94.72%
- Op Margin
- -20.50%
- Net Margin
- -18.66%
- ROE
- -186.46%
- ROIC
- -20.05%
Latest fiscal year · YoY change
- Revenue
- $490.73M+110.5%
- Gross Profit
- $480.39M+113.1%
- Op Income
- $-62,824,000
- Net Income
- $-25,546,000+92.1%
- EPS
- $-0.56+86.3%
- OCF Growth
- +115.9%
- FCF Growth
- +94.0%
- 52W High
- $68.73
- 52W Low
- $22.59
- 50D MA
- $54.61
- 200D MA
- $48.04
- Beta
- 1.12
- RSI (14)
- 38
- Avg Volume
- 1.82M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Travere reported strong third-quarter FILSPARI momentum, with U.S. sales topping $200 million for the first time and management reaffirming confidence in durable growth across IgA nephropathy, FSGS, and the pipeline.· November 2, 2026
- FILSPARI U.S. net product sales reached $200.2 million, up about 120% year over year, and total U.S. net product sales were $220.2 million.
- Management said third-quarter FILSPARI demand stayed strong across IgA nephropathy and FSGS, with 1.93 thousand new-patient start forms and high conversion to paid therapy.
- The company said FSGS access is progressing quickly, with most payers now covering FILSPARI and time to conversion near IgA nephropathy levels.
- Travere reiterated confidence in achieving or exceeding more than $3 billion in annual FILSPARI sales by 2033.
- Pipeline updates included continued progress in HARMONY for pegtibatinase and plans to submit a U.S. IND for civorebrutinib by year-end.
Travere reported third-quarter 2026 total U.S. net product sales of $220.2 million, including $200.2 million of FILSPARI U.S. net product sales, which were up approximately 120% year over year. Thiola and Thiola EC contributed $20 million in U.S. net product sales, and collaboration revenue was $4.4 million, bringing total revenue to $224.6 million. GAAP R&D and SG&A were $168.7 million, including about $23.8 million of non-cash stock-based compensation and depreciation; the company also recognized $113.1 million of IPR&D expense related to the Everest upfront payment. FILSPARI gross-to-net had a one-time benefit of less than $2 million in the quarter, and management expects fourth-quarter net sales to be reduced by about the same amount as specialty pharmacies work down inventory; full-year FILSPARI gross-to-net discounts are still expected in the mid-20% range. Cash, cash equivalents, and marketable securities were approximately $471.8 million as of 9/30/2026.
Eric Dube framed the quarter as another period of execution and momentum, highlighting FILSPARI’s commercial strength, patent progress, and the company’s increasingly durable growth profile. He stressed that FILSPARI is becoming a foundational therapy in IgA nephropathy and is gaining traction in FSGS, while also pointing to earlier diagnosis initiatives and a broader rare kidney disease opportunity. He also spent significant time on his planned transition, saying Travere is entering its next chapter from a position of strength and that he remains confident the company’s best days are ahead.
Christopher Cline said the quarter delivered a new high in revenue, driven mainly by FILSPARI in the U.S. and the first meaningful FSGS contribution. He noted that operating expenses were elevated by HARMONY enrollment and manufacturing for pegtibatinase, plus launch investment in FSGS and IgA nephropathy, while royalty expense was about $8 million. He also highlighted the company’s cash balance of $471.8 million and said the growing revenue base provides a solid foundation to keep investing with discipline.
Analysts focused on FSGS conversion speed, seasonality, and whether the launch is tracking to expectations; management said conversion is faster than the IgA launch and now almost at IgA levels, with most payers already including FILSPARI in FSGS formularies. Questions also centered on IgA sequencing versus BAFF/APRIL therapies, with management arguing FILSPARI remains the preferred kidney-targeted option and that combination use is more likely than switching away from FILSPARI. On pediatrics and access, management said about 10% of FSGS utilization is pediatric and that access/logistics are similar to adults, while they also said they do not see a meaningful trend of patients switching off FILSPARI despite new entrants.
The main bull case is that FILSPARI is showing strong, sustained demand in both approved indications, with high adherence, fast conversion, and broad payer access supporting recurring revenue growth. Management believes the product is positioned as a foundational kidney-targeted therapy and that combination use in IgA nephropathy could expand its role over time.
The main risks are that the IgA nephropathy market is becoming more crowded and dynamic, which management said could create quarter-to-quarter variability in start forms and require more nephrologist time. The company also flagged a roughly $8 million fourth-quarter sales headwind from specialty pharmacy inventory normalization and acknowledged that some FSGS and IgAN trends are still early and could evolve as the market matures.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.0%
- Shares Outstanding
- 95.99M
- Float Shares
- 93.16M
of shares held by institutions
334 13F filers
Buy/sell ratio 0.34. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 11.89M | ▲ 11.89M |
| Jupiter Topco LLC | 11.32M | ▲ 11.32M |
| Blackrock, Inc. | 8.67M | ▲ 652.57K |
| Vanguard Group Inc | 6.31M | ▼ 304.14K |
| Fmr LLC | 5.87M | ▼ 1.23M |
| Bank Of America Corp | 5.82M | ▲ 1.26M |
| State Street Corp | 4.39M | ▲ 131.09K |
| Vanguard Capital Management LLC | 4.19M | ▲ 84.19K |
| Perceptive Advisors LLC | 3.54M | ▼ 209.66K |
| Vanguard Portfolio Management LLC | 3.04M | ▲ 1.50M |
| Geode Capital Management, LLC | 2.42M | ▲ 48.45K |
| Adage Capital Partners Gp, L.L.C. | 2.41M | ▼ 158.87K |
Held by 387 ETFs
Biggest fund positions in TVTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Dube Eric M | other | 200,000 |
| Oct 15, 26 | Dube Eric M | sell | 128,065 |
| Oct 15, 26 | Dube Eric M | sell | 37,270 |
| Oct 15, 26 | Dube Eric M | other | 43,735 |
| Oct 15, 26 | Dube Eric M | sell | 78,400 |
| Oct 15, 26 | Dube Eric M | other | 43,735 |
| Oct 15, 26 | Dube Eric M | other | 200,000 |
| Sep 16, 26 | ROTE WILLIAM E. | other | 57,500 |
| Sep 15, 26 | ROTE WILLIAM E. | other | 39,650 |
| Sep 15, 26 | ROTE WILLIAM E. | other | 39,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TVTX coverage
Recent articles, reports, and earnings notes.
No research on TVTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TVTX report →Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
seekingalpha.com · Nov 16
Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy
seekingalpha.com · Nov 16
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 12
Head-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX)
defenseworld.net · Nov 8
Travere Therapeutics to Participate at Upcoming Investor Conferences
businesswire.com · Nov 3
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
zacks.com · Nov 2
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.